1834-27-1

Usage

Uses

Used in Pharmaceutical Research and Development:
6-chloro-4-methyl-2H-pyridazin-3-one is used as a chemical intermediate for the synthesis of various biologically active compounds. Its unique structure and properties make it a valuable component in the development of new pharmaceuticals with potential therapeutic benefits.
Used in Drug Synthesis:
In the pharmaceutical industry, 6-chloro-4-methyl-2H-pyridazin-3-one is used as a key building block in the creation of novel drug molecules. Its presence in the molecular structure can contribute to the desired pharmacological activity and selectivity of the final drug product.
Used in Disease Treatment Research:
6-chloro-4-methyl-2H-pyridazin-3-one is used as a subject of investigation in research aimed at discovering new treatments for various diseases and disorders. Its pharmacological properties suggest potential applications in medicine, although further studies are required to fully understand its therapeutic potential and safety profile.
Used in Organic Chemistry:
In the field of organic chemistry, 6-chloro-4-methyl-2H-pyridazin-3-one serves as a versatile reagent and substrate for various chemical reactions. Its unique functional groups allow for a range of synthetic transformations, contributing to the advancement of organic chemistry and the development of new chemical compounds.
Used in Medicinal Chemistry:
6-chloro-4-methyl-2H-pyridazin-3-one is employed in medicinal chemistry as a template for designing new drugs with improved pharmacokinetic and pharmacodynamic properties. Its structural features can be modified to optimize drug-target interactions, leading to the development of more effective and safer therapeutic agents.

InChI:InChI=1/C5H5ClN2O/c1-3-2-4(6)7-8-5(3)9/h2H,1H3,(H,8,9)

Upstream product

• 89466-38-6 6-chloro-3-methoxy-4-methylpyridazine 
• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 616-02-4 citraconic acid anhydride 
• 5754-18-7 4-methyl-1,2-dihydropyridazine-3,6-dione 

Downstream Products

• 1395922-81-2 C₂₀H₂₂N₆O 
• 886208-65-7 Minozac 
• 1395922-86-7 C₂₀H₂₂N₆O 
• 1395922-85-6 C₂₀H₂₂N₆ 
• 1395922-84-5 C₁₉H₁₉FN₆ 
• 1395922-83-4 C₂₀H₁₉F₃N₆ 
• 1395922-82-3 C₁₉H₁₉FN₆ 
• 1114573-48-6 (S)-3-((S)-1-(4-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one 
• 1114563-58-4 6-chloro-2,4-dimethylpyridazin-3(2H)-one 

Relevant academic research and scientific papers

Optimization and Synthesis of Pyridazinone Derivatives as Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

The capsid of hepatitis B virus (HBV) plays a vital role in virus DNA replication. Targeting nucleocapsid function has been demonstrated as an effective approach for anti-HBV drug development. A high-throughput screening and mechanism study revealed the h

NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis

Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagonists have been so far disclosed. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. A pyridazine series with improved lipophilic efficiency and with no CYP inhibition liability was identified by scaffold hopping. Further optimization led to the discovery of 40 (GLPG2938), a compound with exquisite potency on a phenotypic IL8 release assay, good pharmacokinetics, and good activity in a bleomycin-induced model of pulmonary fibrosis.

Novel hydrazone derivatives comprising aryl or heteroaryl group substituted at terminal amine and use thereof

The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at a terminal amine group thereof and a use thereof.

2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES

Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS

The present invention discloses compounds according to Formula I, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6a, X, Cy1, Cy2, and the subscript n and m are as defined herein. The present invention relates to antagonists compounds of sphingosine 1-phosphate (SIP) receptor, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, inflammatory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering the compound of the invention.

Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity

(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4, 5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity. A survey of potential bicyclic heteroaromatic replacement subunits for the pyrazolo[1,5-a]pyridine core of KCA-1490 has identified the 4-methoxy-2- (trifluoromethyl)benzo[d]thiazol-7-yl and 8-methoxy-2-(trifluoromethyl)quinolin- 5-yl analogues as dual PDE3/4-inhibitory compounds that potently suppress histamine-induced bronchoconstriction and exhibit anti-inflammatory activity in vivo.

INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1

This invention relates to novel compounds of the Formula (I), (Ia1-10), (Ib1-10), (Ic1-10), (Id1-7), (Ie1-5) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

Identification of aminopyridazine-derived antineuroinflammatory agents effective in an Alzheimer's mouse model

Targeting neuroinflammation may be a new strategy to combat Alzheimer's disease. An aminopyridazine 1b previously reported as a novel antineuroinflammatory agent was considered to have a potential therapeutic effect for Alzheimer's disease. In this study, we further explored the chemical space to identify more potent antineuroinflammatory agents and validate their in vivo efficacy in an animal model. Compound 14 was finally identified as an effective agent with comparable in vivo efficacy to the marketed drug donepezil in counteracting spatial learning and working memory impairment in an Aβ-induced Alzheimer's mouse model.